Table 1 Summary of clinical trials included in these analyses

Dransfield et al.

HZC102871 (NCT01009463) [18]

FF/VI: 50/25 μg, 100/25 μg, 200/25 μg (QD)

VI: 25 μg (QD)

Annual rate of moderate and severe COPD exacerbations

Dransfield et al.

HZC102970 (NCT01017952) [18]

FF/VI: 50/25 μg, 100/25 μg, 200/25 μg (QD)

VI: 25 μg (QD)

Annual rate of moderate and severe COPD exacerbations

Kerwin et al.

HZC112206 (NCT01053988) [19]

FF/VI: 50/25 μg, 100/25 μg (QD)

FF: 100 μg (QD)

VI: 25 μg (QD)

Change from baseline in weighted mean FEV₁ over 0–4 h post-dose at Day 168; Change from baseline in clinic visit trough (pre-bronchodilator and predose) FEV₁ at Day 169

INSPIRE

SCO40036

(NCT00361959) [9]

FP/SAL: 500/50 μg (BD)

TIO: 18 μg (QD)

Rate of healthcare-utilization-based exacerbations of COPD

TRISTAN

SFCB3024 [20, 21]

FP/SAL: 500/50 μg (BD)

FP: 500 μg (BD)

SAL: 50 μg (BD)

Pre-bronchodilator FEV₁ at Week 52

Martinez et al.

HZC112207 (NCT01054885) [22]

FF/VI: 100/25 μg, 200/25 μg (QD)

FF: 100 μg, 200 μg (QD)

VI: 25 μg (QD)

Change from baseline in weighted mean FEV₁ over 0–4 h post-dose at Day 168; change from baseline in trough FEV₁ at Day 169

SCO100470 [23]

FP/SAL: 250/50 μg (BD)

SAL: 50 μg (BD)

Mean trough FEV₁ at endpoint*, mean TDI focal score at endpoint*

SCO30002 [24]

FP/SAL: 500/50 μg (BD)

FP: 500 μg (BD)

Time from the start of treatment to the first moderate or severe exacerbation

Mahler et al.

SFCA3006 [25]

FP/SAL: 500/50 μg (BD)

FP: 500 μg (BD)

SAL: 50 μg (BD)

Mean change from baseline in AM pre-dose and 2-h post-dose FEV₁

Hanania et al.

SFCA3007 [26, 27]

FP/SAL: 250/50 μg (BD)

FP: 250/50 μg (BD)

SAL: 50 μg (BD)

Mean change from baseline in AM pre-dose and 2-h post-dose FEV₁